NCT06655285Completed
The Impact of Inflammatory Adhesion on the Prognosis of Colon Cancer Patients
The Impact of Tumor-associated Inflammatory Adhesion on the Prognosis of Colon Cancer Patients: a Study Based on the SEER and Chinese Multi-center Databases
Source: ClinicalTrials.gov · Last updated 7 Nov 2024
Brief summary (registry, in English)
The purpose of this study is to explore the impact of tumor-associated inflammatory adhesion on the prognosis of colon cancer patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 229 (actual)
- First submitted
- 22 Oct 2024
- Start date
- 24 Oct 2024
- Primary completion date
- 26 Oct 2024
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Colorectal cancer
- NCT number
- NCT06655285
What you commit to
- Study type: Observational
- Participants enrolled: 229
- From 24 Oct 2024 to the primary completion date, 26 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Patients with distant metastasis, recurrent colon cancer and pT4b CRC were excluded.
Who the study is looking for
- The patient was pathologically diagnosed as colon adenocarcinoma by endoscopic biopsy before operation.
- All patients were considered to have tumors invading adjacent organs during surgery
- All patients underwent radical surgery.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.